广西广播电视信息网络股份有限公司2025 年半年度报告 公司代码：600936 公司简称：广西广电 广西广播电视信息网络股份有限公司 2025 年半年度报告 1 / 187 广西广播电视信息网络股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人谢向阳、主管会计工作负责人李一玲及会计机构负责人（会计主管人员）游军 群声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中涉及的未来计划、发展战略等前瞻性描述，不构成公司对投资者的实质承诺，敬请投资 者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 ...

嘉亨家化股份有限公司 2025 年半年度报告全文 嘉亨家化股份有限公司 2025 年半年度报告 2025-023 2025 年 8 月 1 嘉亨家化股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人曾焕彬、主管会计工作负责人陈聪明及会计机构负责人(会计 主管人员)杨英霞声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中如有涉及未来的计划、业绩预测等方面的内容，均不构成本公 司对任何投资者及相关人士的承诺，投资者及相关人士均应对此保持足够的 风险认识，并且应当理解计划、预测与承诺之间的差异。 公司请投资者特别关注在经营过程中可能面临的市场需求波动风险、客 户集中度较高风险、原材料价格波动风险、核心技术更新换代风险、产品质 量问题引起的诉讼、处罚风险、产能扩张投资项目无法实现预期目标的风险 等风险因素。公司在本报告第三节"管理层讨论与分析"之"十、公司面临 的风险和应对 ...

山东南山智尚科技股份有限公司 2025 年半年度报告全文 1 山东南山智尚科技股份有限公司 2025 年半年度报告全文 2 山东南山智尚科技股份有限公司 2025 年半年度报告 2025-079 【披露时间】 山东南山智尚科技股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 公司负责人赵亮、主管会计工作负责人赵亮及会计机构负责人(会计主管人员)徐晓青声明：保 证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告所涉及的未来计划、发展战略等前瞻性陈述，不构成公司对投资者的实质承诺，投资者 及相关人士均应对此保持足够的风险认识，并且应当理解计划、预测与承诺之间的差异，请投资 者注意投资风险。 公司需遵守《深圳证券交易所上市公司自律监管指引第 3 号——行业信息披露》中的"纺织 服装相关业务"的披露要求： 公司在经营管理中可能面临的风险与对策举措已在本报告中第三节"管理层讨论与分析"之 "十一、 ...

深圳市智动力精密技术股份有限公司 2025 年半年度报告全文 深圳市智动力精密技术股份有限公司 2025 年半年度报告 2025-065 2025 年 08 月 1 深圳市智动力精密技术股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人吴雄仰、主管会计工作负责人吴雄仰及会计机构负责人(会计 主管人员)吴雄仰声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本半年度报告中涉及的未来发展战略、经营计划等前瞻性内容属于计划性 事项，能否实现取决于市场状况变化等多种因素，存在不确定性，并不代表 公司对未来的盈利预测，也不构成公司对投资者及相关人士的实质性承诺。 投资者及相关人士均应对此保持足够的风险认识，并且应当理解计划、预测 与承诺之间的差异，敬请投资者注意投资风险。 公司在本半年度报告中详细阐述了未来可能存在的风险因素及对策，具体 内容详见本报告第三节"管理层讨论与分析"中"十 ...

超捷紧固系统（上海）股份有限公司 2025 年半年度报告全文 超捷紧固系统（上海）股份有限公司 2025 年半年度报告 2025-035 2025 年 8 月 1 超捷紧固系统（上海）股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人宋广东、主管会计工作负责人李红涛及会计机构负责人(会计 主管人员)唐群声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中有关未来计划、业绩预测等方面的内容，均不构成本公司对任 何投资者及相关人士的实质承诺，投资者及相关人士均应当对此保持足够的 风险认识，并且应当理解计划、预测与承诺之间的差异。 公司在本半年度报告中详细阐述了未来可能存在的风险因素及对策，具体 内容详见本报告"第三节 管理层讨论与分析"之"十、公司面临的风险和应 对措施"，敬请投资者予以关注相关内容并注意投资风险。 | 第二节 | 公司简介和主要财务指标 6 | | | ...

湖北双环科技股份有限公司 2025 年半年度报告全文 湖北双环科技股份有限公司 2025 年半年度报告 2025 年 8 月 27 日 1 湖北双环科技股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人汪万新、主管会计工作负责人邹涛及会计机构负责人(会计主 管人员)邹涛声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本半年度报告涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承 诺，投资者及相关人士均应当对此保持足够的风险认识，并且应当理解计划、 预测与承诺之间的差异。请投资者注意投资风险。 公司在本报告第三节之"十、公司面临的风险和应对措施"中详细阐述了 可能面对的风险，敬请投资者予以关注。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第二节 | 公司简介和主要财务指标 6 | | --- | --- | | 第三节 | 管理层讨论与分析 9 | ...

证券代码：001230 证券简称：劲旅环境 公告编号：2025-043 劲旅环境科技股份有限公司 2025 年半年度报告 劲旅环境科技股份有限公司 2025 年半年度报告全文 2 2025 年 8 月 1 劲旅环境科技股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人于晓霞、主管会计工作负责人宣迎东及会计机构负责人(会计 主管人员)刘颂元声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本半年度报告涉及未来计划等前瞻性陈述，同时附有相应的警示性陈述， 不构成公司对投资者的实质承诺，投资者及相关人士均应当对此保持足够的 风险认识，并且应当理解计划、预测与承诺之间的差异。 公司已在本半年度报告"第三节管理层讨论与分析"之"十、公司面临的 风险和应对措施"中，描述了可能面对的风险因素及应对措施，敬请投资者 关注相关内容。 公司经本次董事会审议通过的利润分配预案为：以实施权益分派股 ...

江苏亿通高科技股份有限公司 2025 年半年度报告全文 江苏亿通高科技股份有限公司 Jiangsu Yitong High-tech Co., Ltd. （江苏省常熟市通林路 28 号） 2025 年半年度报告 2025 年 8 月 27 日 1 2 江苏亿通高科技股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人黄汪、主管会计工作负责人查青文及会计机构负责人(会计主 管人员)查青文声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的 实质承诺，投资者及相关人士均应对此保持足够的风险认识，并且应当理解 计划、预测与承诺之间的差异，敬请投资者注意投资风险。 （一）终止上市的风险 公司 2024 年度经审计的利润总额、净利润、扣除非经常性损益后的净利 润为亏损，且扣除后的营业收入低于 1 亿元。根据《深圳证券交易所创业 ...

[Part I Important Notice, Table of Contents, and Definitions](index=3&type=section&id=%E7%AC%AC%E4%B8%80%E8%8A%82%20%E9%87%8D%E8%A6%81%E6%8F%90%E7%A4%BA%E3%80%81%E7%9B%AE%E5%BD%95%E5%92%8C%E9%87%8A%E4%B9%89) This section covers important notices, reference documents, and key definitions for the report [1.1 Important Notice](index=3&type=section&id=1.1%20%E9%87%8D%E8%A6%81%E6%8F%90%E7%A4%BA) Board and management affirm report accuracy; no cash dividends or capital reserve conversions are planned - The company's board of directors, supervisory board, and senior management guarantee the truthfulness, accuracy, and completeness of the half-yearly report content[7](index=7&type=chunk) - The company's responsible person, chief accountant, and head of accounting department declare that the financial report is true, accurate, and complete[7](index=7&type=chunk) - The company plans not to distribute cash dividends, send bonus shares, or convert capital reserves into share capital[8](index=8&type=chunk) [1.2 Reference Documents Catalog](index=4&type=section&id=1.2%20%E5%A4%87%E6%9F%A5%E6%96%87%E4%BB%B6%E7%9B%AE%E5%BD%95) This section lists the half-yearly report's reference documents, including signed financial statements and original disclosures - Reference documents include financial statements signed by the company's responsible person, chief accountant, and head of accounting department[10](index=10&type=chunk) - Reference documents include the originals of all company documents and announcements publicly disclosed on the website designated by the China Securities Regulatory Commission during the reporting period[10](index=10&type=chunk) - Reference documents include the original text of the half-yearly report bearing the chairman's signature[11](index=11&type=chunk) [1.3 Definitions](index=5&type=section&id=1.3%20%E9%87%8A%E4%B9%89) This section defines key terms, covering regulatory bodies, legal frameworks, and financial units Main Definitions | Definition Item | Definition Content | | :--- | :--- | | China Securities Regulatory Commission | China Securities Regulatory Commission | | SZSE | Shenzhen Stock Exchange | | The Company, Company, or Tus-Pharma | Tus-Pharma Group Co., Ltd. | | Controlling Shareholder, Tus-Science Service | Tus-Science Service Co., Ltd. | | Reporting Period | January 1, 2025 to June 30, 2025 | [Part II Company Profile and Key Financial Indicators](index=6&type=section&id=%E7%AC%AC%E4%BA%8C%E8%8A%82%20%E5%85%AC%E5%8F%B8%E7%AE%80%E4%BB%8B%E5%92%8C%E4%B8%BB%E8%A6%81%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) This section introduces the company's basic information and presents its key accounting data and financial performance indicators [2.1 Company Profile](index=6&type=section&id=2.1%20%E5%85%AC%E5%8F%B8%E7%AE%80%E4%BB%8B) Tus-Pharma Group Co., Ltd., stock code 000590, is listed on the Shenzhen Stock Exchange, with no changes in contact information Company Basic Information | Indicator | Content | | :--- | :--- | | Stock Abbreviation | Tus-Pharma | | Stock Code | 000590 | | Listed Stock Exchange | Shenzhen Stock Exchange | | Chinese Name | Tus-Pharma Group Co., Ltd. | | Legal Representative | Jiao Qisen | Contact Information | Position | Name | Phone | Email | | :--- | :--- | :--- | :--- | | Board Secretary | Yan Lijun | 0734-8239335 | qdyy0008@tuspharma.cn | | Securities Affairs Representative | Sun Jiaju | 0734-8239335 | qdyy0008@tuspharma.cn | - The company's registered address, office address, website, email, and information disclosure location remained unchanged during the reporting period, as detailed in the 2024 annual report[17](index=17&type=chunk)[18](index=18&type=chunk) [2.2 Key Accounting Data and Financial Indicators](index=7&type=section&id=2.2%20%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) Operating revenue decreased by 2.87%, net loss attributable to shareholders narrowed by 26.61%, and operating cash flow significantly increased by 155.90% Key Accounting Data and Financial Indicators (Year-on-Year Change) | Indicator | Current Reporting Period (yuan) | Prior Year Period (yuan) | Year-on-Year Change | | :--- | :--- | :--- | :--- | | Operating Revenue | 142,437,429.61 | 146,653,368.54 | -2.87% | | Net Profit Attributable to Listed Company Shareholders | -17,170,056.39 | -23,394,630.04 | 26.61% | | Net Cash Flow from Operating Activities | 30,950,220.11 | 12,094,765.90 | 155.90% | | Basic Earnings Per Share (yuan/share) | -0.0717 | -0.0977 | 26.61% | | Weighted Average Return on Net Assets | -2.91% | -3.29% | 0.38% | Key Accounting Data and Financial Indicators (Period-End Change) | Indicator | Current Period-End (yuan) | Prior Year-End (yuan) | Change | | :--- | :--- | :--- | :--- | | Total Assets | 1,009,202,379.73 | 1,013,417,469.23 | -0.42% | | Net Assets Attributable to Listed Company Shareholders | 581,076,063.03 | 598,246,119.42 | -2.87% | [2.3 Differences in Accounting Data Under Domestic and International Accounting Standards](index=7&type=section&id=2.3%20%E5%A2%83%E5%86%85%E5%A4%96%E4%BC%9A%E8%AE%A1%E5%87%86%E5%88%99%E4%B8%8B%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%B7%AE%E5%BC%82) The company reports no differences in net profit and net assets between Chinese and international or overseas accounting standards - The company reports no differences in net profit and net assets between financial reports disclosed under international accounting standards and Chinese accounting standards during the reporting period[21](index=21&type=chunk) - The company reports no differences in net profit and net assets between financial reports disclosed under overseas accounting standards and Chinese accounting standards during the reporting period[22](index=22&type=chunk) [2.4 Non-Recurring Gains and Losses Items and Amounts](index=7&type=section&id=2.4%20%E9%9D%9E%E7%BB%8F%E5%B8%B8%E6%80%A7%E6%8D%9F%E7%9B%8A%E9%A1%B9%E7%9B%AE%E5%8F%8A%E9%87%91%E9%A2%9D) Non-recurring gains and losses totaled 5,482,116.95 yuan, primarily from asset disposal, government grants, and financial asset fair value changes Non-Recurring Gains and Losses Items and Amounts | Item | Amount (yuan) | | :--- | :--- | | Gains or losses from disposal of non-current assets | 3,444,349.77 | | Government grants recognized in current profit or loss | 2,448,669.81 | | Gains or losses from changes in fair value of financial assets and liabilities held by non-financial enterprises, and gains or losses from disposal of financial assets and liabilities | 299,874.90 | | Fund occupation fees received from non-financial enterprises recognized in current profit or loss | 11,560.00 | | Other non-operating income and expenses apart from the above | 90,898.68 | | Other gains and losses items that meet the definition of non-recurring gains and losses | 70,861.54 | | Less: Income tax impact | 883,873.11 | | Minority interest impact (after tax) | 224.64 | | **Total** | **5,482,116.95** | - Other gains and losses items that meet the definition of non-recurring gains and losses are handling fees for withholding individual income tax[25](index=25&type=chunk) [Part III Management Discussion and Analysis](index=9&type=section&id=%E7%AC%AC%E4%B8%89%E8%8A%82%20%E7%AE%A1%E7%90%86%E5%B1%82%E8%AE%A8%E8%AE%BA%E4%B8%8E%E5%88%86%E6%9E%90) This section provides an in-depth analysis of the company's business operations, performance drivers, core competencies, and financial status [3.1 Company's Main Business Activities During the Reporting Period](index=9&type=section&id=3.1%20%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E5%85%AC%E5%8F%B8%E4%BB%8E%E4%BA%8B%E7%9A%84%E4%B8%BB%E8%A6%81%E4%B8%9A%E5%8A%A1) The company operates in the pharmaceutical and health sector, focusing on traditional Chinese medicine, chemical drugs, and health foods, with a core product "Guhan Yangshenjing" [3.1.1 Industry Overview](index=9&type=section&id=3.1.1%20%E8%A1%8C%E4%B8%9A%E6%83%85%E5%86%B5) The pharmaceutical industry, a strategic sector, is developing steadily with policy support for traditional Chinese medicine, but faces challenges from healthcare reforms and rising costs - The pharmaceutical industry maintains a high-quality development trend under national policy guidance, with traditional Chinese medicine gaining development opportunities due to its "preventive treatment" advantages and policy support[27](index=27&type=chunk) - Healthcare system reforms (review and approval, centralized procurement, medical insurance payment reform) and rising costs of raw materials, packaging materials, energy, and labor have put pressure on the pharmaceutical industry, limiting revenue and profit growth[28](index=28&type=chunk) [3.1.2 Main Business, Products, and Market Position](index=9&type=section&id=3.1.2%20%E4%B8%BB%E8%A6%81%E4%B8%9A%E5%8A%A1%E3%80%81%E4%BA%A7%E5%93%81%E5%8F%8A%E5%9C%B0%E4%BD%8D) The company's core business spans traditional Chinese medicine, chemical drugs, and health foods, featuring the "Guhan Yangshenjing" product, a national secret technology, and a "China Time-Honored Brand" status - The company deeply cultivates the pharmaceutical and health sector, with businesses covering traditional Chinese medicine, chemical drugs, and health foods[29](index=29&type=chunk) - The core traditional Chinese medicine product, "Guhan Yangshenjing," originates from an ancient Mawangdui Han tomb prescription, is a "quasi-drug" pure traditional Chinese medicine preparation with both therapeutic and health-preserving functions, and its traditional production technique is listed as a Hunan Provincial Intangible Cultural Heritage[29](index=29&type=chunk) - The company owns over 110 drug varieties, more than 60 patents, including 6 exclusive varieties like "Guhan Yangshenjing," and the "Guhan" China Well-known Trademark and "China Time-Honored Brand" status[30](index=30&type=chunk) [3.1.3 Company's Business Model](index=10&type=section&id=3.1.3%20%E5%85%AC%E5%8F%B8%E7%BB%8F%E8%90%A5%E6%A8%A1%E5%BC%8F) The company's business model involves procurement through bidding, production based on market demand and GMP standards, and sales through agency distribution, direct supply, and e-commerce - The procurement department strictly follows procurement regulations, with bulk materials, packaging materials, and medicinal herbs primarily procured through bidding and inquiry comparison[31](index=31&type=chunk) - The production model is planned based on market demand, sales, production capacity, and safety stock, and strictly adheres to the standards of the "Pharmacopoeia of the People's Republic of China" and "Good Manufacturing Practice for Pharmaceutical Products"[32](index=32&type=chunk) - The sales model primarily adopts agency distribution (provincial or national agency) and direct supply, controlled sales, and direct sales (for large and medium-sized chains and hospitals), while actively exploring new retail and e-commerce marketing models[33](index=33&type=chunk)[34](index=34&type=chunk) [3.2 Performance Drivers During the Reporting Period](index=10&type=section&id=3.2%20%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E4%B8%9A%E7%BB%A9%E9%A9%B1%E5%8A%A8%E5%9B%A0%E7%B4%A0) The company drove performance through channel integration, brand marketing, cost control, R&D innovation, and digitalization, despite a decline in total operating revenue - The company's management focuses on the "One Body, Two Wings" development strategy, with branded traditional Chinese medicine as the core, specialty APIs and health consumer products as the two wings, and internal reform, cost reduction, efficiency improvement, and external investment and M&A as driving engines[35](index=35&type=chunk) - The company enhances brand influence by deepening provincial channel integration, expanding out-of-province recruitment, strengthening e-commerce operations, and innovating marketing models[36](index=36&type=chunk) - The company reduces procurement costs by dynamically analyzing market conditions through its supply chain information system and flexibly adjusting payment terms, while strengthening comprehensive budget management to strictly control expenses[37](index=37&type=chunk) - R&D innovation achieved multiple breakthroughs, with 12 projects under research, new product launches, 14 hospital preparations developed, 4 new outsourced cooperation projects, and industry-university-research cooperation intentions reached with universities[38](index=38&type=chunk) - The company promotes the construction of a digital information system for the entire industry chain, earning the title of "Hunan Province 2025 Advanced Intelligent Factory"[39](index=39&type=chunk) - The company strengthens human resource management, building multiple promotion channels, implementing contract-based appointments for middle and grassroots managers, and improving the training mechanism for R&D personnel to stimulate talent vitality[40](index=40&type=chunk) [3.3 Core Competitiveness Analysis](index=12&type=section&id=3.3%20%E6%A0%B8%E5%BF%83%E7%AB%9E%E4%BA%89%E5%8A%9B%E5%88%86%E6%9E%90) The company's core competitiveness stems from its "China Time-Honored Brand" status, R&D capabilities, stringent GMP quality management, and experienced talent - The company owns the "China Time-Honored Brand," with its core product Guhan Yangshenjing listed as a Hunan Provincial Intangible Cultural Heritage, enjoying a good market reputation[42](index=42&type=chunk) - The company has provincial enterprise technology centers and other R&D platforms, enhancing technological innovation capabilities through independent R&D and industry-university-research cooperation, and building a Traditional Chinese Medicine Smart Industrial Park[43](index=43&type=chunk) - The company has established a rigorous quality management system, based on GMP, to strictly control the entire production process, and has been awarded the title of "Hunan Province Manufacturing Quality Benchmark"[44](index=44&type=chunk) - The company possesses an experienced R&D team and core management team, and is committed to establishing long-term incentive mechanisms to attract and retain outstanding talent[45](index=45&type=chunk) [3.4 Analysis of Main Business](index=12&type=section&id=3.4%20%E4%B8%BB%E8%90%A5%E4%B8%9A%E5%8A%A1%E5%88%86%E6%9E%90) Operating revenue decreased by 2.87% due to market conditions, but net loss attributable to shareholders narrowed by 26.61%, and operating cash flow significantly increased by 155.90% due to performance compensation Key Financial Data Year-on-Year Changes | Indicator | Current Reporting Period (yuan) | Prior Year Period (yuan) | Year-on-Year Change | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 142,437,429.61 | 146,653,368.54 | -2.87% | | | Net Profit Attributable to Listed Company Shareholders | -17,170,056.39 | -23,394,630.04 | 26.61% | | | Net Cash Flow from Operating Activities | 30,950,220.11 | 12,094,765.90 | 155.90% | Primarily due to receipt of equity acquisition performance compensation | | Net Cash Flow from Financing Activities | 39,536,052.11 | -3,170,536.53 | 1,346.98% | Primarily due to increased bank borrowings and decreased bank loan repayments compared to the prior year | | Net Increase in Cash and Cash Equivalents | 43,507,368.37 | -18,201,659.91 | 339.03% | Primarily due to receipt of equity acquisition performance compensation | Operating Revenue Composition (by Industry, Product, Region) | Category | Item | Current Reporting Period Amount (yuan) | Proportion of Operating Revenue | Prior Year Period Amount (yuan) | Proportion of Operating Revenue | Year-on-Year Change | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | By Industry | Pharmaceutical Manufacturing | 133,916,320.41 | 94.02% | 139,000,907.40 | 94.78% | -3.66% | | By Product | Traditional Chinese Medicine Company and Marketing Company Products | 113,136,318.25 | 79.43% | 117,156,337.55 | 79.89% | -3.43% | | | Guangdong Xiantong Company Products | 20,337,966.81 | 14.28% | 19,008,614.09 | 12.96% | 6.99% | | | Pharmaceutical Company Products | 442,035.35 | 0.31% | 2,835,955.76 | 1.93% | -84.41% | | By Region | Within Province | 105,724,104.97 | 74.22% | 103,603,639.36 | 70.65% | 2.05% | | | Outside Province | 36,713,324.64 | 25.78% | 43,049,729.18 | 29.35% | -14.72% | Gross Profit Margin Changes in Main Business | Category | Item | Gross Profit Margin | Gross Profit Margin Change from Prior Year Period | | :--- | :--- | :--- | :--- | | By Industry | Pharmaceutical Manufacturing | 44.55% | -2.44% | | By Product | Traditional Chinese Medicine Company and Marketing Company Products | 44.33% | -1.63% | | | Guangdong Xiantong Company Products | 45.81% | -4.65% | | | Pharmaceutical Company Products | 44.52% | -22.06% | | By Region | Within Province | 40.23% | -10.57% | | | Outside Province | 56.11% | 17.60% | [3.5 Analysis of Non-Main Business](index=14&type=section&id=3.5%20%E9%9D%9E%E4%B8%BB%E8%90%A5%E4%B8%9A%E5%8A%A1%E5%88%86%E6%9E%90) The company had no non-main business activities during the reporting period - The company had no non-main business activities during the reporting period[53](index=53&type=chunk) [3.6 Analysis of Assets and Liabilities](index=14&type=section&id=3.6%20%E8%B5%84%E4%BA%A7%E5%8F%8A%E8%B4%9F%E5%80%BA%E7%8A%B6%E5%86%B5%E5%88%86%E6%9E%90) Total assets and net assets attributable to shareholders slightly decreased, with increases in cash, construction in progress, short-term and long-term borrowings, and decreases in accounts receivable and fixed assets Significant Changes in Asset Composition | Item | Current Period-End Amount (yuan) | Proportion of Total Assets | Prior Year-End Amount (yuan) | Proportion of Total Assets | Proportion Change | | :--- | :--- | :--- | :--- | :--- | :--- | | Monetary Funds | 216,542,305.41 | 21.46% | 177,291,724.42 | 17.49% | 3.97% | | Accounts Receivable | 3,807,886.89 | 0.38% | 7,633,469.83 | 0.75% | -0.37% | | Inventories | 128,639,921.98 | 12.75% | 124,783,406.23 | 12.31% | 0.44% | | Construction in Progress | 18,393,092.65 | 1.82% | 8,812,400.02 | 0.87% | 0.95% | | Short-term Borrowings | 30,000,000.00 | 2.97% | 754,536.30 | 0.07% | 2.90% | | Long-term Borrowings | 95,054,792.00 | 9.42% | 82,223,970.92 | 8.11% | 1.31% | Assets and Liabilities Measured at Fair Value | Item | Beginning Balance (yuan) | Amount Purchased in Current Period (yuan) | Amount Sold in Current Period (yuan) | Ending Balance (yuan) | | :--- | :--- | :--- | :--- | :--- | | Trading Financial Assets | 0.00 | 135,000,000.00 | 135,000,000.00 | 0.00 | | Other Non-current Financial Assets | 20,028,049.72 | 0.00 | 0.00 | 20,028,049.72 | | Receivables Financing | 56,900,645.47 | | | 49,147,782.69 | | **Total** | **76,928,695.19** | **135,000,000.00** | **135,000,000.00** | **69,175,832.41** | Asset Rights Restriction Status | Item | Period-End Book Value (yuan) | Restricted Type | Restricted Status | | :--- | :--- | :--- | :--- | | Monetary Funds | 12,446,249.29 | Bank acceptance bill margin | Not freely usable | | Notes Receivable | 26,632,407.44 | Notes pool for issuing notes receivable | Not freely usable | [3.7 Investment Analysis](index=15&type=section&id=3.7%20%E6%8A%95%E8%B5%84%E7%8A%B6%E5%86%B5%E5%88%86%E6%9E%90) The company had no significant equity, securities, or derivative investments, but is undertaking major non-equity projects for a raw material warehouse and a pharmaceutical technology park - The company had no securities investments or derivative investments during the reporting period[61](index=61&type=chunk)[62](index=62&type=chunk) Significant Non-Equity Investments | Project Name | Investment Method | Cumulative Actual Investment Amount as of Reporting Period-End (yuan) | Project Progress | | :--- | :--- | :--- | :--- | | Original Raw Material Warehouse | Self-built | 8,230,099.62 | 50.61% | | Guhan Chemical (Pharmaceutical) Technology Park Phase I Construction Project | Self-built | 4,945,516.05 | 3.20% | [3.8 Significant Asset and Equity Disposals](index=17&type=section&id=3.8%20%E9%87%8D%E5%A4%A7%E8%B5%84%E4%BA%A7%E5%92%8C%E8%82%A1%E6%9D%83%E5%87%BA%E5%94%AE) The company did not dispose of any significant assets or equity during the reporting period - The company did not dispose of significant assets during the reporting period[64](index=64&type=chunk) - The company did not dispose of significant equity during the reporting period[65](index=65&type=chunk) [3.9 Analysis of Major Holding and Participating Companies](index=17&type=section&id=3.9%20%E4%B8%BB%E8%A6%81%E6%8E%A7%E8%82%A1%E5%8F%82%E8%82%A1%E5%85%AC%E5%8F%B8%E5%88%86%E6%9E%90) Major subsidiaries faced challenges, with net profits declining for Guhan Traditional Chinese Medicine and Guangdong Xiantong, while Hengyang Pharmaceutical continued to incur losses due to production halts and personnel burden Major Subsidiary Operating Performance | Company Name | Business Nature | Registered Capital (yuan) | Operating Revenue (yuan) | Net Profit (yuan) | | :--- | :--- | :--- | :--- | :--- | | Guhan Traditional Chinese Medicine Co., Ltd. | Pharmaceutical Manufacturing | 160,000,000.00 | 106,040,861.07 | 6,183,008.50 | | Guangdong Xiantong Pharmaceutical Co., Ltd. | Pharmaceutical Manufacturing | 21,080,000.00 | 21,417,755.00 | -1,260,505.13 | | Tus-Guhan Group Hengyang Pharmaceutical Co., Ltd. | Pharmaceutical Manufacturing | 10,000,000.00 | 484,411.06 | -9,975,424.77 | | Hunan Tus-Pharma Marketing Co., Ltd. | Pharmaceutical Wholesale and Retail | 10,000,000.00 | 113,975,687.11 | -8,776,226.71 | - Guhan Traditional Chinese Medicine Co., Ltd.'s net profit decreased by **59.97%** year-on-year, primarily due to reduced revenue and increased raw material prices[66](index=66&type=chunk) - Guangdong Xiantong Pharmaceutical Co., Ltd.'s net profit decreased by **387.96%** year-on-year, with revenue impacted by centralized procurement policies[67](index=67&type=chunk) - Hengyang Pharmaceutical Co., Ltd. continued to incur losses due to the suspension of its western medicine production line and heavy personnel burden[67](index=67&type=chunk) - The marketing company's performance declined overall, affected by consumption downgrades and a downturn in upstream performance[68](index=68&type=chunk) [3.10 Structured Entities Controlled by the Company](index=18&type=section&id=3.10%20%E5%85%AC%E5%8F%B8%E6%8E%A7%E5%88%B6%E7%9A%84%E7%BB%93%E6%9E%84%E5%8C%96%E4%B8%BB%E4%BD%93%E6%83%85%E5%86%B5) The company did not control any structured entities during the reporting period - The company had no structured entities under its control during the reporting period[69](index=69&type=chunk) [3.11 Risks Faced by the Company and Countermeasures](index=18&type=section&id=3.11%20%E5%85%AC%E5%8F%B8%E9%9D%A2%E4%B8%B4%E7%9A%84%E9%A3%8E%E9%99%A9%E5%92%8C%E5%BA%94%E5%AF%B9%E6%8E%AA%E6%96%BD) The company faces risks from a single product structure, raw material price volatility, and subsidiary losses, addressed by market stabilization, R&D, cost control, and asset restructuring - The company is highly dependent on its flagship product "Guhan Yangshenjing," posing a risk of a single product structure[69](index=69&type=chunk) - Prices of traditional Chinese medicinal materials are subject to various factors and may fluctuate, affecting the company's product costs and profitability[70](index=70&type=chunk) - The wholly-owned subsidiary Hengyang Pharmaceutical Co., Ltd. is in a loss-making state due to an aging product structure, inverted production and sales prices, suspension of its western medicine production line, and heavy personnel burden[71](index=71&type=chunk) - Countermeasures include maintaining market stability for core products, increasing R&D investment in new products, strengthening market price monitoring, implementing cost management, and accelerating product structure adjustment and asset disposal for the pharmaceutical company[69](index=69&type=chunk)[70](index=70&type=chunk)[71](index=71&type=chunk) [3.12 Implementation of Market Value Management System and Valuation Enhancement Plan](index=18&type=section&id=3.12%20%E5%B8%82%E5%80%BC%E7%AE%A1%E7%90%86%E5%88%B6%E5%BA%A6%E5%92%8C%E4%BC%B0%E5%80%BC%E6%8F%90%E5%8D%87%E8%AE%A1%E5%88%92%E7%9A%84%E5%88%B6%E5%AE%9A%E8%90%BD%E5%AE%9E%E6%83%85%E5%86%B5) The company did not formulate a market value management system or disclose a valuation enhancement plan during the reporting period - The company did not formulate a market value management system during the reporting period[72](index=72&type=chunk) - The company did not disclose a valuation enhancement plan during the reporting period[73](index=73&type=chunk) [3.13 Implementation of 'Quality and Return Dual Improvement' Action Plan](index=19&type=section&id=3.13%20%22%E8%B4%A8%E9%87%8F%E5%9B%9E%E6%8A%A5%E5%8F%8C%E6%8F%90%E5%8D%87%22%E8%A1%8C%E5%8A%A8%E6%96%B9%E6%A1%88%E8%B4%AF%E5%BD%BB%E8%90%BD%E5%AE%9E%E6%83%85%E5%86%B5) The company did not disclose an announcement regarding the "Quality and Return Dual Improvement" action plan during the reporting period - The company did not disclose an announcement regarding the "Quality and Return Dual Improvement" action plan during the reporting period[73](index=73&type=chunk) [Part IV Corporate Governance, Environment, and Society](index=20&type=section&id=%E7%AC%AC%E5%9B%9B%E8%8A%82%20%E5%85%AC%E5%8F%B8%E6%B2%BB%E7%90%86%E3%80%81%E7%8E%AF%E5%A2%83%E5%92%8C%E7%A4%BE%E4%BC%9A) This section details changes in governance personnel, profit distribution plans, environmental disclosures, and the company's social responsibility initiatives [4.1 Changes in Directors, Supervisors, and Senior Management](index=20&type=section&id=4.1%20%E5%85%AC%E5%8F%B8%E8%91%A3%E4%BA%8B%E3%80%81%E7%9B%91%E4%BA%8B%E3%80%81%E9%AB%98%E7%BA%A7%E7%AE%A1%E7%90%86%E4%BA%BA%E5%91%98%E5%8F%98%E5%8A%A8%E6%83%85%E5%86%B5) There were no changes in the company's directors, supervisors, and senior management during the reporting period - The company's directors, supervisors, and senior management had no changes during the reporting period[75](index=75&type=chunk) [4.2 Profit Distribution and Capital Reserve Conversion to Share Capital During the Reporting Period](index=20&type=section&id=4.2%20%E6%9C%AC%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%88%A9%E6%B6%A6%E5%88%86%E9%85%8D%E5%8F%8A%E8%B5%84%E6%9C%AC%E5%85%AC%E7%A7%AF%E9%87%91%E8%BD%AC%E5%A2%9E%E8%82%A1%E6%9C%AC%E6%83%85%E5%86%B5) The company plans no cash dividends, bonus shares, or capital reserve conversions to share capital for the half-year period - The company plans no cash dividends, bonus shares, or capital reserve conversions to share capital for the half-year period[76](index=76&type=chunk) [4.3 Implementation of Equity Incentive Plans, Employee Stock Ownership Plans, or Other Employee Incentive Measures](index=20&type=section&id=4.3%20%E5%85%AC%E5%8F%B8%E8%82%A1%E6%9D%83%E6%BF%80%E5%8A%B1%E8%AE%A1%E5%88%92%E3%80%81%E5%91%98%E5%B7%A5%E6%8C%81%E8%82%A1%E8%AE%A1%E5%88%92%E6%88%96%E5%85%B6%E4%BB%96%E5%91%98%E5%B7%A5%E6%BF%80%E5%8A%B1%E6%8E%AA%E6%96%BD%E7%9A%84%E5%AE%9E%E6%96%BD%E6%83%85%E5%86%B5) The company had no equity incentive plans, employee stock ownership plans, or other employee incentive measures in place during the reporting period - The company had no equity incentive plans, employee stock ownership plans, or other employee incentive measures and their implementation during the reporting period[77](index=77&type=chunk) [4.4 Environmental Information Disclosure](index=20&type=section&id=4.4%20%E7%8E%AF%E5%A2%83%E4%BF%A1%E6%81%AF%E6%8A%AB%E9%9C%B2%E6%83%85%E5%86%B5) The company and three major subsidiaries are listed as legally required environmental information disclosure enterprises, with public access to their respective reports - The listed company and its three major subsidiaries are included in the list of enterprises required to disclose environmental information by law[78](index=78&type=chunk) Subsidiaries Included in the List of Enterprises Required to Disclose Environmental Information by Law | No. | Enterprise Name | Query Index for Environmental Information Disclosure Report | | :--- | :--- | :--- | | 1 | Guhan Traditional Chinese Medicine Co., Ltd. | https://permit.mee.gov.cn/perxxgkinfo/xkgkAction!xkgk.action?xkgk=getxxgkContent&dataid=5a2e687e4d9b4300b36ec9a226a78873 | | 2 | Guangdong Xiantong Co., Ltd. | https://www app.gdeei.cn/gdeepub/front/dal/report/list | | 3 | Tus-Guhan Group Hengyang Pharmaceutical Co., Ltd. (Luojinqiao Plant) | http://yfpl.sthjt.hunan.gov.cn:8181/hnyfpl/frontal/index.html/home/enterpriseInfo?XTXH=aad66665-6644-4f03-8175-18ad5261b90d&XH=1682667375017029835264&year=2024&reportType=1 | [4.5 Social Responsibility](index=20&type=section&id=4.5%20%E7%A4%BE%E4%BC%9A%E8%B4%A3%E4%BB%BB%E6%83%85%E5%86%B5) The company actively fulfills its social responsibilities by organizing volunteer activities, promoting ethnic unity, and supporting rural revitalization with financial aid and product procurement - The company aims to build the "No. 1 Brand of Chinese Health Experts" and is committed to the mission of "promoting national pharmaceutical industry and benefiting people's health," adhering to a healthy, green, and harmonious development model[79](index=79&type=chunk) - During the reporting period, the company organized over **100 volunteer participations** in social volunteer service activities and promoted the "Guhan Industrial Tourism Scenic Area—Characteristic Traditional Chinese Medicine Culture Promotes Three Exchanges" project[79](index=79&type=chunk) - The company continued its rural revitalization paired assistance work, allocating **50,000 yuan** in assistance funds to Zhouchong Village, Zhajiang Town, Hengyang County, and procuring **124,500 yuan** worth of local agricultural products for consumption assistance[80](index=80&type=chunk) [Part V Significant Matters](index=22&type=section&id=%E7%AC%AC%E4%BA%94%E8%8A%82%20%E9%87%8D%E8%A6%81%E4%BA%8B%E9%A1%B9) This section covers commitments, related party transactions, guarantees, litigation, and other significant events affecting the company [5.1 Commitments](index=22&type=section&id=5.1%20%E6%89%BF%E8%AF%BA%E4%BA%8B%E9%A1%B9) The company reports no unfulfilled or overdue commitments from its actual controller, shareholders, related parties, or the company itself - The company reports no commitments made by its actual controller, shareholders, related parties, acquirers, or the company itself that were fulfilled during the reporting period or were overdue and unfulfilled as of the end of the reporting period[82](index=82&type=chunk) [5.2 Non-Operating Funds Occupied by Controlling Shareholder and Other Related Parties](index=22&type=section&id=5.2%20%E6%8E%A7%E8%82%A1%E8%82%A1%E4%B8%9C%E5%8F%8A%E5%85%B6%E4%BB%96%E5%85%B3%E8%81%94%E6%96%B9%E9%9D%9E%E7%BB%8F%E8%90%A5%E6%80%A7%E5%8D%A0%E7%94%A8%E8%B5%84%E9%87%91%E6%83%85%E5%86%B5) The company reports no non-operating funds occupied by its controlling shareholder or other related parties during the reporting period - The company reports no non-operating funds occupied by its controlling shareholder or other related parties during the reporting period[83](index=83&type=chunk) [5.3 Irregular External Guarantees](index=22&type=section&id=5.3%20%E8%BF%9D%E8%A7%84%E5%AF%B9%E5%A4%96%E6%8B%85%E4%BF%9D%E6%83%85%E5%86%B5) The company had no irregular external guarantees during the reporting period - The company had no irregular external guarantees during the reporting period[84](index=84&type=chunk) [5.4 Appointment and Dismissal of Accounting Firms](index=22&type=section&id=5.4%20%E8%81%98%E4%BB%BB%E3%80%81%E8%A7%A3%E8%81%98%E4%BC%9A%E8%AE%A1%E5%B8%88%E4%BA%8B%E5%8A%A1%E6%89%80%E6%83%85%E5%86%B5) The company's half-yearly report was not audited - The company's half-yearly report was not audited[85](index=85&type=chunk) [5.5 Board of Directors' and Supervisory Board's Explanations on 'Non-Standard Audit Reports' from Accounting Firms](index=22&type=section&id=5.5%20%E8%91%A3%E4%BA%8B%E4%BC%9A%E3%80%81%E7%9B%91%E4%BA%8B%E4%BC%9A%E5%AF%B9%E4%BC%9A%E8%AE%A1%E5%B8%88%E4%BA%8B%E5%8A%A1%E6%89%80%22%E9%9D%9E%E6%A0%87%E5%87%86%E5%AE%A1%E8%AE%A1%E6%8A%A5%E5%91%8A%22%E7%9A%84%E8%AF%B4%E6%98%8E) The company's board of directors and supervisory board provided no explanations regarding "non-standard audit reports" from accounting firms - The company's board of directors and supervisory board provided no explanations regarding "non-standard audit reports" from accounting firms for the current reporting period[86](index=86&type=chunk) [5.6 Bankruptcy and Reorganization Matters](index=22&type=section&id=5.6%20%E7%A0%B4%E4%BA%A7%E9%87%8D%E6%95%B4%E7%9B%B8%E5%85%B3%E4%BA%8B%E9%A1%B9) The company did not experience any bankruptcy or reorganization matters during the reporting period - The company did not experience any bankruptcy or reorganization matters during the reporting period[86](index=86&type=chunk) [5.7 Litigation Matters](index=22&type=section&id=5.7%20%E8%AF%89%E8%AE%BC%E4%BA%8B%E9%A1%B9) The company had no significant litigation, arbitration, or other litigation matters during the reporting period - The company had no significant litigation or arbitration matters during the current reporting period[87](index=87&type=chunk) - The company had no other litigation matters during the reporting period[87](index=87&type=chunk) [5.8 Penalties and Rectification](index=23&type=section&id=5.8%20%E5%A4%84%E7%BD%9A%E5%8F%8A%E6%95%B4%E6%94%B9%E6%83%85%E5%86%B5) The company had no penalties or rectification situations during the reporting period - The company had no penalties or rectification situations during the reporting period[88](index=88&type=chunk) [5.9 Integrity Status of the Company, its Controlling Shareholder, and Actual Controller](index=23&type=section&id=5.9%20%E5%85%AC%E5%8F%B8%E5%8F%8A%E5%85%B6%E6%8E%A7%E8%82%A1%E8%82%A1%E4%B8%9C%E3%80%81%E5%AE%9E%E9%99%85%E6%8E%A7%E5%88%B6%E4%BA%BA%E7%9A%84%E8%AF%9A%E4%BF%A1%E7%8A%B6%E5%86%B5) The company, its controlling shareholder, and actual controller maintained good integrity status during the reporting period - The company reports no integrity issues concerning itself, its controlling shareholder, or its actual controller during the reporting period[89](index=89&type=chunk) [5.10 Significant Related Party Transactions](index=23&type=section&id=5.10%20%E9%87%8D%E5%A4%A7%E5%85%B3%E8%81%94%E4%BA%A4%E6%98%93) The company had no significant related party transactions, including those related to daily operations, asset/equity acquisitions/disposals, joint investments, or related party debts - The company had no related party transactions related to daily operations during the reporting period[89](index=89&type=chunk) - The company had no related party transactions involving asset or equity acquisitions or disposals during the reporting period[90](index=90&type=chunk) - The company had no related party debt transactions during the reporting period[92](index=92&type=chunk) [5.11 Significant Contracts and Their Performance](index=24&type=section&id=5.11%20%E9%87%8D%E5%A4%A7%E5%90%88%E5%90%8C%E5%8F%8A%E5%85%B6%E5%B1%A5%E8%A1%8C%E6%83%85%E5%86%B5) The company had no custody, contracting, leasing, or wealth management activities, but provided significant guarantees to subsidiaries totaling **26,054,800 yuan** [5.11.1 Custody, Contracting, and Leasing Matters](index=24&type=section&id=5.11.1%20%E6%89%98%E7%AE%A1%E3%80%81%E6%89%BF%E5%8C%85%E3%80%81%E7%A7%9F%E8%B5%81%E4%BA%8B%E9%A1%B9%E6%83%85%E5%86%B5) The company had no custody, contracting, or leasing arrangements during the reporting period - The company had no custody arrangements during the reporting period[96](index=96&type=chunk) - The company had no contracting arrangements during the reporting period[97](index=97&type=chunk) - The company had no leasing arrangements during the reporting period[98](index=98&type=chunk) [5.11.2 Significant Guarantees](index=24&type=section&id=5.11.2%20%E9%87%8D%E5%A4%A7%E6%8B%85%E4%BF%9D) The company provided joint liability guarantees to subsidiaries, with an approved total of **180,000,000 yuan** and an actual outstanding balance of **26,054,800 yuan**, representing **4.48%** of net assets Company Guarantees to Subsidiaries | Guaranteed Entity Name | Guarantee Limit (10,000 yuan) | Actual Guarantee Amount (10,000 yuan) | Guarantee Type | Guarantee Period | | :--- | :--- | :--- | :--- | :--- | | Guhan Traditional Chinese Medicine Co., Ltd. | 2,000 | 1,760.15 | Joint liability guarantee | Six years from the day after the expiration of the main debt | | Guhan Traditional Chinese Medicine Co., Ltd. | 3,000 | | Joint liability guarantee | Three years from the day after the expiration of the main debt | | Guhan Traditional Chinese Medicine Co., Ltd. | 3,000 | | Joint liability guarantee | One year from the day after the expiration of the main debt | | Hunan Tus-Pharma Technology Co., Ltd. | 10,000 | 845.33 | Joint liability guarantee | Fifteen years from the day after the expiration of the main debt | - As of the end of the reporting period, the total approved guarantee limit for subsidiaries was **180,000,000 yuan**, and the actual outstanding guarantee balance for subsidiaries was **26,054,800 yuan**[101](index=101&type=chunk) - The total actual guarantee amount accounts for **4.48%** of the company's net assets[101](index=101&type=chunk) [5.11.3 Wealth Management](index=25&type=section&id=5.11.3%20%E5%A7%94%E6%89%98%E7%90%86%E8%B4%A2) The company had no wealth management activities during the reporting period - The company had no wealth management activities during the reporting period[102](index=102&type=chunk) [5.11.4 Other Significant Contracts](index=25&type=section&id=5.11.4%20%E5%85%B6%E4%BB%96%E9%87%8D%E5%A4%A7%E5%90%88%E5%90%8C) The company had no other significant contracts during the reporting period - The company had no other significant contracts during the reporting period[103](index=103&type=chunk) [5.12 Explanation of Other Significant Matters](index=25&type=section&id=5.12%20%E5%85%B6%E4%BB%96%E9%87%8D%E5%A4%A7%E4%BA%8B%E9%A1%B9%E7%9A%84%E8%AF%B4%E6%98%8E) The controlling shareholder's **58,606,962 shares** were judicially auctioned and acquired by Hunan Sailexian, leading to a change in the company's control - On June 16, 2025, **58,606,962 shares** held by the company's controlling shareholder, Tus-Science Service Co., Ltd., were publicly auctioned by the Beijing Financial Court due to a financial loan contract dispute[105](index=105&type=chunk) - On July 15, 2025, Hunan Sailexian Management Consulting Service Partnership (Limited Partnership) successfully bid **1,007,392,612.46 yuan** for the aforementioned shares[105](index=105&type=chunk) - As of August 11, 2025, the transfer registration of these shares was completed, Tus-Science Service Co., Ltd. no longer holds company shares, and Hunan Sailexian holds **24.47%** of the company's total share capital[106](index=106&type=chunk) [5.13 Significant Matters of Company Subsidiaries](index=26&type=section&id=5.13%20%E5%85%AC%E5%8F%B8%E5%AD%90%E5%85%AC%E5%8F%B8%E9%87%8D%E5%A4%A7%E4%BA%8B%E9%A1%B9) The company's subsidiaries had no significant matters during the reporting period - The company's subsidiaries had no significant matters during the reporting period[107](index=107&type=chunk) [Part VI Share Changes and Shareholder Information](index=27&type=section&id=%E7%AC%AC%E5%85%AD%E8%8A%82%20%E8%82%A1%E4%BB%BD%E5%8F%98%E5%8A%A8%E5%8F%8A%E8%82%A1%E4%B8%9C%E6%83%85%E5%86%B5) This section details the company's share capital structure, shareholder composition, and any changes in shareholdings or control [6.1 Share Change Status](index=27&type=section&id=6.1%20%E8%82%A1%E4%BB%BD%E5%8F%98%E5%8A%A8%E6%83%85%E5%86%B5) The company's total share capital, restricted shares, and unrestricted shares remained unchanged during the reporting period Share Change Status | Item | Number of Shares Before Change (shares) | Proportion Before Change | Number of Shares After Change (shares) | Proportion After Change | | :--- | :--- | :--- | :--- | :--- | | I. Restricted Shares | 99,840 | 0.04% | 99,840 | 0.04% | | II. Unrestricted Shares | 239,371,427 | 99.96% | 239,371,427 | 99.96% | | III. Total Shares | 239,471,267 | 100.00% | 239,471,267 | 100.00% | - During the reporting period, the reasons for share changes, approval status, transfer status, and progress of share repurchase implementation were all not applicable or unchanged[111](index=111&type=chunk) [6.2 Securities Issuance and Listing](index=28&type=section&id=6.2%20%E8%AF%81%E5%88%B8%E5%8F%91%E8%A1%8C%E4%B8%8E%E4%B8%8A%E5%B8%82%E6%83%85%E5%86%B5) The company had no securities issuance or listing activities during the reporting period - The company had no securities issuance or listing activities during the reporting period[112](index=112&type=chunk) [6.3 Number of Shareholders and Shareholding Status](index=28&type=section&id=6.3%20%E5%85%AC%E5%8F%B8%E8%82%A1%E4%B8%9C%E6%95%B0%E9%87%8F%E5%8F%8A%E6%8C%81%E8%82%A1%E6%83%85%E5%86%B5) The company had **15,025** common shareholders at period-end, with Tus-Science Service Co., Ltd. (**24.47%**) and Hengyang Hongxiang State-owned Investment (Holdings) Group Co., Ltd. (**19.11%**) as the top two shareholders - The total number of common shareholders at the end of the reporting period was **15,025**[112](index=112&type=chunk) Shareholding Status of Shareholders Holding 5% or More or Top 10 Shareholders | Shareholder Name | Shareholder Nature | Shareholding Percentage | Number of Shares Held at Period-End (shares) | Share Status | Number (shares) | | :--- | :--- | :--- | :--- | :--- | :--- | | Tus-Science Service Co., Ltd. | Domestic Non-State-owned Legal Person | 24.47% | 58,606,962.00 | Frozen | 58,606,962.00 | | Hengyang Hongxiang State-owned Investment (Holdings) Group Co., Ltd. | State-owned Legal Person | 19.11% | 45,757,337.00 | Not Applicable | 0 | | Peng Tielan | Domestic Natural Person | 4.06% | 9,733,110.00 | Not Applicable | 0 | | Beijing Huaqing Investment Co., Ltd. | Domestic Non-State-owned Legal Person | 1.90% | 4,544,451.00 | Pledged | 2,270,000.00 | - Tus-Science Service Co., Ltd. and Beijing Huaqing Investment Co., Ltd. have an associated relationship and are parties acting in concert[113](index=113&type=chunk) [6.4 Changes in Shareholdings of Directors, Supervisors, and Senior Management](index=30&type=section&id=6.4%20%E8%91%A3%E4%BA%8B%E3%80%81%E7%9B%91%E4%BA%8B%E5%92%8C%E9%AB%98%E7%BA%A7%E7%AE%A1%E7%90%86%E4%BA%BA%E5%91%98%E6%8C%81%E8%82%A1%E5%8F%98%E5%8A%A8) There were no changes in the shareholdings of the company's directors, supervisors, and senior management during the reporting period - The company's directors, supervisors, and senior management had no changes in shareholdings during the reporting period[115](index=115&type=chunk) [6.5 Changes in Controlling Shareholder or Actual Controller](index=30&type=section&id=6.5%20%E6%8E%A7%E8%82%A1%E8%82%A1%E4%B8%9C%E6%88%96%E5%AE%9E%E9%99%85%E6%8E%A7%E5%88%B6%E4%BA%BA%E5%8F%98%E6%9B%B4%E6%83%85%E5%86%B5) The company's controlling shareholder changed during the reporting period, but the actual controller remained unchanged - The controlling shareholder changed during the reporting period, while the actual controller did not change during the reporting period[116](index=116&type=chunk) [6.6 Preferred Share Related Information](index=30&type=section&id=6.6%20%E4%BC%98%E5%85%88%E8%82%A1%E7%9B%B8%E5%85%B3%E6%83%85%E5%86%B5) The company had no preferred shares during the reporting period - The company had no preferred shares during the reporting period[116](index=116&type=chunk) [Part VII Bond Related Information](index=31&type=section&id=%E7%AC%AC%E4%B8%83%E8%8A%82%20%E5%80%BA%E5%88%B8%E7%9B%B8%E5%85%B3%E6%83%85%E5%86%B5) This section provides information regarding the company's bond-related activities [7.1 Bond Related Information](index=31&type=section&id=7.1%20%E5%80%BA%E5%88%B8%E7%9B%B8%E5%85%B3%E6%83%85%E5%86%B5) The company had no bond-related information during the reporting period - The company had no bond-related information during the reporting period[118](index=118&type=chunk) [Part VIII Financial Report](index=32&type=section&id=%E7%AC%AC%E5%85%AB%E8%8A%82%20%E8%B4%A2%E5%8A%A1%E6%8A%A5%E5%91%8A) This section presents the company's unaudited financial statements, including balance sheets, income statements, cash flow statements, and statements of changes in owners' equity [8.1 Audit Report](index=32&type=section&id=8.1%20%E5%AE%A1%E8%AE%A1%E6%8A%A5%E5%91%8A) The company's half-yearly financial report was not audited - The company's half-yearly financial report was not audited[120](index=120&type=chunk) [8.2 Financial Statements](index=32&type=section&id=8.2%20%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8) This section provides the company's 2025 half-yearly consolidated and parent company balance sheets, income statements, cash flow statements, and statements of changes in owners' equity [8.2.1 Consolidated Balance Sheet](index=32&type=section&id=8.2.1%20%E5%90%88%E5%B9%B6%E8%B5%84%E4%BA%A7%E8%B4%9F%E5%80%BA%E8%A1%A8) As of June 30, 2025, the company's consolidated total assets were **1,009,202,379.73 yuan**, with total liabilities of **425,232,969.15 yuan** and total owners' equity of **583,969,410.58 yuan** Consolidated Balance Sheet Key Data (Period-End) | Item | Period-End Balance (yuan) | | :--- | :--- | | Total Assets | 1,009,202,379.73 | | Total Current Assets | 494,634,836.59 | | Total Non-current Assets | 514,567,543.14 | | Total Liabilities | 425,232,969.15 | | Total Owners' Equity | 583,969,410.58 | [8.2.2 Parent Company Balance Sheet](index=34&type=section&id=8.2.2%20%E6%AF%8D%E5%85%AC%E5%8F%B8%E8%B5%84%E4%BA%A7%E8%B4%9F%E5%80%BA%E8%A1%A8) As of June 30, 2025, the parent company's total assets were **870,413,903.92 yuan**, with total liabilities of **306,750,628.18 yuan** and total owners' equity of **563,663,275.74 yuan** Parent Company Balance Sheet Key Data (Period-End) | Item | Period-End Balance (yuan) | | :--- | :--- | | Total Assets | 870,413,903.92 | | Total Current Assets | 159,303,380.78 | | Total Non-current Assets | 711,110,523.14 | | Total Liabilities | 306,750,628.18 | | Total Owners' Equity | 563,663,275.74 | [8.2.3 Consolidated Income Statement](index=36&type=section&id=8.2.3%20%E5%90%88%E5%B9%B6%E5%88%A9%E6%B6%A6%E8%A1%A8) For the first half of 2025, the company's consolidated total operating revenue was **142,437,429.61 yuan**, with a net loss of **17,263,541.22 yuan** and basic earnings per share of **-0.0717 yuan** Consolidated Income Statement Key Data | Item | H1 2025 (yuan) | H1 2024 (yuan) | | :--- | :--- | :--- | | Total Operating Revenue | 142,437,429.61 | 146,653,368.54 | | Operating Profit | -15,056,123.10 | -20,014,746.38 | | Net Profit | -17,263,541.22 | -23,276,437.01 | | Net Profit Attributable to Parent Company Shareholders | -17,170,056.39 | -23,394,630.04 | | Basic Earnings Per Share | -0.0717 | -0.0977 | [8.2.4 Parent Company Income Statement](index=38&type=section&id=8.2.4%20%E6%AF%8D%E5%85%AC%E5%8F%B8%E5%88%A9%E6%B6%A6%E8%A1%A8) For the first half of 2025, the parent company's operating revenue was **7,474,896.21 yuan**, with a net loss of **1,221,304.14 yuan** and basic earnings per share of **-0.0051 yuan** Parent Company Income Statement Key Data | Item | H1 2025 (yuan) | H1 2024 (yuan) | | :--- | :--- | :--- | | Operating Revenue | 7,474,896.21 | 7,875,596.61 | | Operating Profit | -544,329.63 | -10,256,533.75 | | Net Profit | -1,221,304.14 | -10,706,693.75 | | Basic Earnings Per Share | -0.0051 | -0.0447 | [8.2.5 Consolidated Cash Flow Statement](index=39&type=section&id=8.2.5%20%E5%90%88%E5%B9%B6%E7%8E%B0%E9%87%91%E6%B5%81%E9%87%8F%E8%A1%A8) For the first half of 2025, net cash flow from operating activities was **30,950,220.11 yuan**, from investing activities was **-26,978,903.85 yuan**, and from financing activities was **39,536,052.11 yuan** Consolidated Cash Flow Statement Key Data | Item | H1 2025 (yuan) | H1 2024 (yuan) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 30,950,220.11 | 12,094,765.90 | | Net Cash Flow from Investing Activities | -26,978,903.85 | -27,125,889.28 | | Net Cash Flow from Financing Activities | 39,536,052.11 | -3,170,536.53 | | Net Increase in Cash and Cash Equivalents | 43,507,368.37 | -18,201,659.91 | | Cash and Cash Equivalents at Period-End | 204,096,056.12 | 159,862,025.76 | [8.2.6 Parent Company Cash Flow Statement](index=40&type=section&id=8.2.6%20%E6%AF%8D%E5%85%AC%E5%8F%B8%E7%8E%B0%E9%87%91%E6%B5%81%E9%87%8F%E8%A1%A8) For the first half of 2025, net cash flow from operating activities was **-1,202,113.99 yuan**, from investing activities was **-14,418,026.55 yuan**, and from financing activities was **23,071,435.98 yuan** Parent Company Cash Flow Statement Key Data | Item | H1 2025 (yuan) | H1 2024 (yuan) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | -1,202,113.99 | 30,675,121.07 | | Net Cash Flow from Investing Activities | -14,418,026.55 | -8,011,299.54 | | Net Cash Flow from Financing Activities | 23,071,435.98 | -7,223,217.40 | | Net Increase in Cash and Cash Equivalents | 7,451,295.44 | 15,440,604.13 | | Cash and Cash Equivalents at Period-End | 23,131,021.59 | 66,143,045.55 | [8.2.7 Consolidated Statement of Changes in Owners' Equity](index=41&type=section&id=8.2.7%20%E5%90%88%E5%B9%B6%E6%89%80%E6%9C%89%E8%80%85%E6%9D%83%E7%9B%8A%E5%8F%98%E5%8A%A8%E8%A1%A8) As of June 30, 2025, consolidated owners' equity totaled **583,969,410.58 yuan**, a decrease from the beginning of the period, primarily due to the net loss Consolidated Statement of Changes in Owners' Equity | Item | Beginning Balance (yuan) | Change in Current Period (yuan) | Ending Balance (yuan) | | :--- | :--- | :--- | :--- | | Total Owners' Equity Attributable to Parent Company | 598,246,119.42 | -17,170,056.39 | 581,076,063.03 | | Minority Interests | 2,986,832.38 | -93,484.83 | 2,893,347.55 | | Total Owners' Equity | 601,232,951.80 | -17,263,541.22 | 583,969,410.58 | [8.2.8 Parent Company Statement of Changes in Owners' Equity](index=45&type=section&id=8.2.8%20%E6%AF%8D%E5%85%AC%E5%8F%B8%E6%89%80%E6%9C%89%E8%80%85%E6%9D%83%E7%9B%8A%E5%8F%98%E5%8A%A8%E8%A1%A8) As of June 30, 2025, parent company owners' equity totaled **563,663,275.74 yuan**, a slight decrease from the beginning of the period, mainly due to the net loss Parent Company Statement of Changes in Owners' Equity | Item | Beginning Balance (yuan) | Change in Current Period (yuan) | Ending Balance (yuan) | | :--- | :--- | :--- | :--- | | Total Owners' Equity | 564,884,579.88 | -1,221,304.14 | 563,663,275.74 | [8.3 Company Basic Information](index=48&type=section&id=8.3%20%E5%85%AC%E5%8F%B8%E5%9F%BA%E6%9C%AC%E6%83%85%E5%86%B5) Tus-Pharma Group Co., Ltd., established in 1993 and listed in 1996, primarily engages in pharmaceutical manufacturing and health-related businesses, with Tus-Science Service Co., Ltd. as its parent company - Tus-Pharma Group Co., Ltd. was established in November 1993 and listed on the Shenzhen Stock Exchange on January 19, 1996, operating in the pharmaceutical manufacturing industry[153](index=153&type=chunk) - As of June 30, 2025, the company's restricted tradable shares were **95,040 shares** (**0.04%** of total share capital), and unrestricted tradable shares were **239,376,227 shares** (**99.96%** of total share capital)[153](index=153&type=chunk) - The company's main business activities include pharmaceutical internet information services, health food production, food sales, disinfection equipment sales, alcohol sales, and comprehensive health services such as health consulting, wellness, and traditional Chinese medicine health services[154](index=154&type=chunk) - As of June 30, 2025, the company's parent company is Tus-Science Service Co., Ltd., and the company has no ultimate controlling party[154](index=154&type=chunk) [8.4 Basis of Financial Statement Preparation](index=49&type=section&id=8.4%20%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8%E7%9A%84%E7%BC%96%E5%88%B6%E5%9F%BA%E7%A1%80) The financial statements are prepared in accordance with Chinese Accounting Standards and CSRC regulations, based on a going concern assumption - These financial statements are prepared in accordance with the "Enterprise Accounting Standards" issued by the Ministry of Finance and relevant provisions of the China Securities Regulatory Commission's "Information Disclosure and Reporting Rules for Companies Issuing Securities No. 15 - General Provisions for Financial Reports"[155](index=155&type=chunk) - These financial statements are prepared on a going concern basis[156](index=156&type=chunk) [8.5 Significant Accounting Policies and Estimates](index=49&type=section&id=8.5%20%E9%87%8D%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%94%BF%E7%AD%96%E5%8F%8A%E4%BC%9A%E8%AE%A1%E4%BC%B0%E8%AE%A1) This section details the company's significant accounting policies and estimates, covering financial instruments, inventory valuation, revenue recognition, and other key accounting treatments - The company adheres to enterprise accounting standards, accurately and completely reflecting its financial position, operating results, and cash flows[158](index=158&type=chunk) - Financial assets are classified as measured at amortized cost, at fair value through other comprehensive income, and at fair value through profit or loss[169](index=169&type=chunk) - Inventories are initially measured at cost, valued using the first-in, first-out method when issued, and accounted for using the perpetual inventory system[185](index=185&type=chunk)[186](index=186&type=chunk)[187](index=187&type=chunk) - The company recognizes revenue when it satisfies a performance obligation in the contract, which is when the customer obtains control of the related goods or services[226](index=226&type=chunk) - The company elects not to recognize right-of-use assets and lease liabilities for short-term leases and leases of low-value assets, expensing related lease payments on a straight-line basis or as part of the cost of related assets[247](index=247&type=chunk) [8.6 Taxation](index=67&type=section&id=8.6%20%E7%A8%8E%E9%A1%B9) The company's main taxes include VAT, urban maintenance and construction tax, and corporate income tax, with some subsidiaries benefiting from preferential tax rates as high-tech or small-profit enterprises Main Tax Categories and Rates | Tax Category | Taxable Basis | Tax Rate | | :--- | :--- | :--- | | Value-Added Tax | Revenue from sales of goods and taxable services | 6%; 9%; 13% | | Urban Maintenance and Construction Tax | Amount of turnover tax payable | 7% | | Corporate Income Tax | Taxable income | 15%; 20%; 25% | | Property Tax | Original value of property or rental income | 1.2%; 12% | | Education Surcharge | Amount of turnover tax payable | 3% | | Local Education Surcharge | Amount of turnover tax payable | 2% | - Guhan Traditional Chinese Medicine Co., Ltd. and Guangdong Xiantong Pharmaceutical Co., Ltd., as high-tech enterprises, enjoy a **15%** corporate income tax rate for the current year[256](index=256&type=chunk)[257](index=257&type=chunk) - Some subsidiaries qualify as small-profit enterprises and, from January 1, 2023, to December 31, 2027, calculate their taxable income at **25%** and pay corporate income tax at a **20%** rate[258](index=258&type=chunk) [8.7 Notes to Consolidated Financial Statement Items](index=68&type=section&id=8.7%20%E5%90%88%E5%B9%B6%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8%E9%A1%B9%E7%9B%AE%E6%B3%A8%E9%87%8A) This section provides detailed notes on consolidated financial statement items, including restricted cash, accounts receivable, inventory, goodwill impairment, and pledged long-term borrowings - Monetary funds at period-end totaled **216,542,305.41 yuan**, of which **12,446,249.29 yuan** is restricted as bank acceptance bill margin[260](index=260&type=chunk) - Accounts receivable at period-end had a book value of **3,807,886.89 yuan**, with an allowance for doubtful accounts of **63,627,488.26 yuan**, representing a **94.35%** provision rate[271](index=271&type=chunk) - Inventories at period-end had a book value of **128,639,921.98 yuan**, including inventory impairment provisions of **3,784,995.95 yuan** for finished goods[299](index=299&type=chunk)[301](index=301&type=chunk) - Goodwill had an original book value of **137,143,972.34 yuan**, with an impairment provision of **123,940,374.07 yuan**, primarily related to the Guangdong Xiantong Pharmaceutical Co., Ltd. asset group[337](index=337&type=chunk)[339](index=339&type=chunk)[340](index=340&type=chunk)[341](index=341&type=chunk) - Long-term borrowings at period-end totaled **95,054,792.00 yuan**, primarily including pledged borrowings of **70,000,000.00 yuan** (secured by 100% equity of Guangdong Xiantong Pharmaceutical Co., Ltd.)[385](index=385&type=chunk) [8.8 Research and Development Expenses](index=99&type=section&id=8.8%20%E7%A0%94%E5%8F%91%E6%94%AF%E5%87%BA) Total R&D expenses for the reporting period were **8,292,249.34 yuan**, entirely expensed, primarily comprising salaries, materials, depreciation, and outsourced R&D fees R&D Expense Composition | Item | Amount Incurred in Current Period (yuan) | Amount Incurred in Prior Period (yuan) | | :--- | :--- | :--- | | Salaries, Welfare, and Social Insurance | 4,534,005.01 | 4,008,924.73 | | Material Input | 396,467.26 | 505,880.33 | | Depreciation, Amortization, etc. | 1,250,672.84 | 360,656.05 | | Outsourced R&D Fees | 1,173,776.70 | 1,510,708.74 | | Other | 937,327.53 | 308,359.99 | | **Total** | **8,292,249.34** | **6,694,529.84** | | Of which: Expensed R&D | 8,292,249.34 | 6,694,529.84 | [8.9 Interests in Other Entities](index=99&type=section&id=8.9%20%E5%9C%A8%E5%85%B6%E4%BB%96%E4%B8%BB%E4%BD%93%E4%B8%AD%E7%9A%84%E6%9D%83%E7%9B%8A) The company holds interests in various subsidiaries across pharmaceutical and health sectors, with a zero carrying value for its long-term equity investment in the associate Tus-Guhan Group Hunan Pharmaceutical Co., Ltd. Major Subsidiary Composition | Subsidiary Name | Business Nature | Shareholding Percentage (Direct) | Shareholding Percentage (Indirect) | | :--- | :--- | :--- | :--- | | Guhan Traditional Chinese Medicine Co., Ltd. | Pharmaceutical Manufacturing | 100.00% | | | Tus-Guhan Group Hengyang Pharmaceutical Co., Ltd. | Pharmaceutical Manufacturing | 100.00% | | | Guangdong Xiantong Pharmaceutical Co., Ltd. | Pharmaceutical Manufacturing | 100.00% | | | Hunan Tus-Pharma Marketing Co., Ltd. | Pharmaceutical Wholesale and Retail | 100.00% | | | Hengyang Guhan Health Technology Development Co., Ltd. | Nutrition and Health Consulting Services | | 100.00% | - The company's long-term equity investment in the associate Tus-Guhan Group Hunan Pharmaceutical Co., Ltd. has a book value of **0 yuan** due to its continuous losses, resulting in negative net assets at period-end[311](index=311&type=chunk) Summary Financial Information for Insignificant Joint Ventures and Associates | Item | Period-End Balance/Current Period Amount (yuan) | | :--- | :--- | | Net Profit of Associates | -454,214.49 | | Total Comprehensive Income of Associates | -454,214.49 | [8.10 Government Grants](index=101&type=section&id=8.10%20%E6%94%BF%E5%BA%9C%E8%A1%A5%E5%8A%A9) At the end of the reporting period, deferred income from government grants totaled **45,245,802.96 yuan**, with **2,433,900.00 yuan** added and **1,178,446.06 yuan** recognized as other income Liability Items Involving Government Grants | Accounting Account | Beginning Balance (yuan) | New Grants in Current Period (yuan) | Amount Transferred to Other Income in Current Period (yuan) | Ending Balance (yuan) | Related to Assets/Income | | :--- | :--- | :--- | :--- | :--- | :--- | | Deferred Income | 43,990,349.02 | 2,433,900.00 | 1,178,446.06 | 45,245,802.96 | Asset-related | Government Grants Recognized in Current Profit or Loss | Accounting Account | Amount Incurred in Current Period (yuan) | Amount Incurred in Prior Period (yuan) | | :--- | :--- | :--- | | Deferred Income | 1,178,446.06 | 961,616.88 | | Other Income | 1,248,051.12 | 1,310,804.43 | [8.11 Risks Related to Financial Instruments](index=101&type=section&id=8.11%20%E4%B8%8E%E9%87%91%E8%9E%8D%E5%B7%A5%E5%85%B7%E7%9B%B8%E5%85%B3%E7%9A%84%E9%A3%8E%E9%99%A9) The company manages credit, liquidity, and market risks (including interest rate and other price risks) through credit policies, cash flow monitoring, and appropriate debt portfolios - The company faces credit risk, liquidity risk, and market risk (including exchange rate risk, interest rate risk, and other price risks)[463](index=463&type=chunk) - The company controls its credit risk exposure by assessing customer creditworthiness and regularly monitoring credit records[465](index=465&type=chunk) - The company manages liquidity risk by monitoring cash balances, readily marketable securities, and rolling forecasts of cash flows for the next 12 months[466](index=466&type=chunk) - The company manages interest costs by maintaining an appropriate mix of fixed-rate and variable-rate debt[471](index=471&type=chunk) [8.12 Fair Value Disclosure](index=103&type=section&id=8.12%20%E5%85%AC%E5%85%81%E4%BB%B7%E5%80%BC%E7%9A%84%E6%8A%AB%E9%9C%B2) The company's fair value measured assets, primarily receivables financing and other non-current financial assets, totaled **69,175,832.41 yuan**, all classified as Level 3 fair value measurements Period-End Fair Value of Assets and Liabilities Measured at Fair Value | Item | Level 3 Fair Value Measurement (yuan) | Total (yuan) | | :--- | :--- | :--- | | Receivables Financing | 49,147,782.69 | 49,147,782.69 | | Other Non-current Financial Assets | 20,028,049.72 | 20,028,049.72 | | **Total Assets Continuously Measured at Fair Value** | **69,175,832.41** | **69,175,832.41** | - Fair value measurement inputs are categorized into three levels: Level 1 for quoted prices in active markets, Level 2 for observable inputs, and Level 3 for unobservable inputs[476](index=476&type=chunk) [8.13 Related Parties and Related Party Transactions](index=104&type=section&id=8.13%20%E5%85%B3%E8%81%94%E6%96%B9%E5%8F%8A%E5%85%B3%E8%81%94%E4%BA%A4%E6%98%93) The company's parent company is Tus-Science Service Co., Ltd., with no ultimate controlling party, and the company has a contract liability of **143,694.41 yuan** with its associate, Tus-Guhan Group Hunan Pharmaceutical Co., Ltd. - The company's parent company is Tus-Science Service Co., Ltd., with registered capital of **1,036,900,900 yuan**, and both its shareholding and voting rights percentage are **24.47%**[477](index=477&type=chunk) - The company has no ultimate controlling party[477](index=477&type=chunk) - The associate Tus-Guhan Group Hunan Pharmaceutical Co., Ltd. engaged in related party transactions with the company[479](index=479&type=chunk) Related Party Payables | Item Name | Related Party | Period-End Book Balance (yuan) | Beginning Balance (yuan) | | :--- | :--- | :--- | :--- | | Contract Liabilities | Tus-Guhan Group Hunan Pharmaceutical Co., Ltd. | 143,694.41 | 143,694.41 | [8.14 Commitments and Contingencies](index=104&type=section&id=8.14%20%E6%89%BF%E8%AF%BA%E5%8F%8A%E6%88%96%E6%9C%89%E4%BA%8B%E9%A1%B9) The company had no significant commitments or material contingencies requiring disclosure at the balance sheet date - There were no significant commitments at the balance sheet date[483](index=483&type=chunk) - The company had no material contingencies requiring disclosure[483](index=483&type=chunk) [8.15 Post-Balance Sheet Events](index=105&type=section&id=8.15%20%E8%B5%84%E4%BA%A7%E8%B4%9F%E5%80%BA%E8%A1%A8%E6%97%A5%E5%90%8E%E4%BA%8B%E9%A1%B9) The company had no significant sales returns or other post-balance sheet events during the reporting period - The current period does not involve significant sales returns occurring after the balance sheet date[484](index=484&type=chunk) - There were no other post-balance sheet events in the current period[485](index=485&type=chunk) [8.16 Other Significant Matters](index=105&type=section&id=8.16%20%E5%85%B6%E4%BB%96%E9%87%8D%E8%A6%81%E4%BA%8B%E9%A1%B9) The company's reporting segments are Traditional Chinese Medicine & Health, Western Medicine, and Other Businesses, with Traditional Chinese Medicine & Health contributing most revenue and assets, but all segments reporting losses Financial Information by Reporting Segment | Item | Traditional Chinese Medicine & Health Production and Sales Business (yuan) | Western Medicine Production and Sales Business (yuan) | Other Businesses (yuan) | Total (yuan) | | :--- | :--- | :--- | :--- | :--- | | External Transaction Revenue | 139,797,731.62 | 484,411.06 | 2,155,286.93 | 142,437,429.61 | | Total Pr

2025 年半年度报告 公告编号：2025-041 2025 年 08 月 1 创业慧康科技股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 创业慧康科技股份有限公司 2025 年半年度报告全文 创业慧康科技股份有限公司 公司负责人张吕峥、主管会计工作负责人郑奇及会计机构负责人(会计主 管人员)郑奇声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 报告所包含的前瞻性分析系基于各种假设，不同假设可能导致分析结果 出现重大不同。报告中的内容和意见仅供参考，并不构成对本公司股票买卖 的建议，在任何情况下，本报告中的前瞻性描述和分析信息或所表述的意见 并不构成对任何人的投资建议。除法律或规则规定必须承担的责任外，本公 司不对使用本报告及其内容所引发的任何直接或间接损失负任何责任。 公司在经营管理中可能面临的主要风险与相应举措已在本报告第三节 "管理层讨论与分析"之"十、公司面临的风险和应对措施"部分予以描述。 敬请广大投资者注意风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | | | | 第二节 | 公司简介和主要财务指标 ...